{"id":485668,"date":"2021-05-03T08:03:58","date_gmt":"2021-05-03T12:03:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/"},"modified":"2021-05-03T08:03:58","modified_gmt":"2021-05-03T12:03:58","slug":"incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/","title":{"rendered":"Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021"},"content":{"rendered":"

<\/p>\n

Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021<\/b><\/p>\n

WILMINGTON, Del.–(BUSINESS WIRE<\/a>)–
\nIncyte (Nasdaq:INCY) today announced that multiple abstracts from its dermatology portfolio highlighting data on ruxolitinib cream, a selective JAK1\/JAK2 inhibitor designed for topical application, in patients with atopic dermatitis (AD) will be presented at the Society for Investigative Dermatology (SID) Virtual Meeting 2021, held virtually from May 3-8, 2021.\n<\/p>\n

\n\u201cAtopic dermatitis is a chronic inflammatory skin condition that can have serious impacts on patients\u2019 quality of life,\u201d said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte. \u201cWe are pleased to present data that highlight the potential of ruxolitinib cream as an effective topical treatment for patients with AD at the SID Virtual Meeting and are thankful for the SID\u2019s efforts in hosting this event virtually for the second year to promote ongoing scientific exchange that could lead to improved outcomes for patients.\u201d\n<\/p>\n

\nKey abstracts from Incyte-sponsored studies include:\n<\/p>\n

ePoster Talks<\/span><\/b><\/p>\n

Effects of Ruxolitinib Cream in Patients with Atopic Dermatitis with Head and\/or Neck Involvement <\/b>(Abstract #311. Patient Population Research)\n<\/p>\n

Ruxolitinib Cream Rapidly Decreases Skin Pain in Atopic Dermatitis <\/b>(Abstract #325. Patient Population Research)\n<\/p>\n

Itch-Free State in Patients with Atopic Dermatitis Treated with Ruxolitinib Cream <\/b>(Abstract #313. Patient Population Research)\n<\/p>\n

Efficacy of Ruxolitinib Cream in Adults and Adolescents with Atopic Comorbidities <\/b>(Abstract #329. Patient Population Research)\n<\/p>\n

ePoster Presentations<\/span><\/b><\/p>\n

Atopic Dermatitis: Patient Characteristics and Patient-Reported Outcomes on Topical Therapy <\/b>(Abstract #333. Patient Population Research)\n<\/p>\n

\nAll presentations are available on-demand through May 31, 2021. Session details and listings of all presentations are available in the SID meeting program: https:\/\/www.sidannualmeeting.org\/information\/meeting-program-attendee-user-guide\/<\/a>.\n<\/p>\n

About Ruxolitinib Cream<\/b><\/p>\n

\nRuxolitinib cream is a proprietary formulation of Incyte\u2019s selective JAK1\/JAK2 inhibitor ruxolitinib that has been designed for topical application. Ruxolitinib cream is currently in Phase 3 development for the treatment of atopic dermatitis (TRuE-AD) and for the treatment of adolescents and adults with vitiligo (TRuE-V). Incyte has worldwide rights for the development and commercialization of ruxolitinib cream.\n<\/p>\n

About Incyte Dermatology<\/b><\/p>\n

\nIncyte\u2019s science-first approach and expertise in immunology has formed the foundation of the company. In Dermatology, the Company\u2019s research and development efforts are focused on leveraging our knowledge of the JAK-STAT pathway to identify and develop topical and oral therapies with the potential to modulate immune pathways driving uncontrolled inflammation and help restore normal immune function.\n<\/p>\n

\nCurrently, Incyte is exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo and hidradenitis suppurativa. To learn more, visit the Dermatology section of Incyte.com<\/a>.\n<\/p>\n

About Incyte<\/b><\/p>\n

\nIncyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com<\/a> and follow @Incyte<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nExcept for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company\u2019s ongoing clinical development program of ruxolitinib cream, its , atopic dermatitis and other dermatology programs generally, and whether or when ruxolitinib cream will be approved or commercially available for use in humans in the U.S. or elsewhere, its presentation plans for the upcoming SID meeting and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.\n<\/p>\n

\nThese forward-looking statements are based on the Company\u2019s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company\u2019s clinical trials, supply chain and other third-party providers, and development and discovery operations; determinations made by the U.S. FDA and other regulatory authorities outside of the United States; the efficacy or safety of the Company\u2019s products; the acceptance of the Company\u2019s products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company\u2019s reports filed with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2020. The Company disclaims any intent or obligation to update these forward-looking statements.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210503005077\/en\/<\/a><\/span><\/p>\n

Media
\n<\/b>
Catalina Loveman
\n
+1 302 498 6171
\n
cloveman@incyte.com<\/a><\/p>\n

\nJenifer Antonacci
\n
+1 302 498 7036
\n
jantonacci@incyte.com<\/a><\/p>\n

Investors
\n<\/b>
Christine Chiou
\n
+1 302 274 4773
\n
cchiou@incyte.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Delaware<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health General Health Research Pharmaceutical Science Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021 WILMINGTON, Del.–(BUSINESS WIRE)– Incyte (Nasdaq:INCY) today announced that multiple abstracts from its dermatology portfolio highlighting data on ruxolitinib cream, a selective JAK1\/JAK2 inhibitor designed for topical application, in patients with atopic dermatitis (AD) will be presented at the Society for Investigative Dermatology (SID) Virtual Meeting 2021, held virtually from May 3-8, 2021. \u201cAtopic dermatitis is a chronic inflammatory skin condition that can have serious impacts on patients\u2019 quality of life,\u201d said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte. \u201cWe are pleased to present data that highlight the potential of ruxolitinib cream as an effective … <\/p>\n

Continue reading “Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-485668","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nIncyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021 WILMINGTON, Del.–(BUSINESS WIRE)– Incyte (Nasdaq:INCY) today announced that multiple abstracts from its dermatology portfolio highlighting data on ruxolitinib cream, a selective JAK1\/JAK2 inhibitor designed for topical application, in patients with atopic dermatitis (AD) will be presented at the Society for Investigative Dermatology (SID) Virtual Meeting 2021, held virtually from May 3-8, 2021. \u201cAtopic dermatitis is a chronic inflammatory skin condition that can have serious impacts on patients\u2019 quality of life,\u201d said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte. \u201cWe are pleased to present data that highlight the potential of ruxolitinib cream as an effective … Continue reading "Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-03T12:03:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210503005077r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021\",\"datePublished\":\"2021-05-03T12:03:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\\\/\"},\"wordCount\":845,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210503005077r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\\\/\",\"name\":\"Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210503005077r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-05-03T12:03:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210503005077r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210503005077r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/","og_locale":"en_US","og_type":"article","og_title":"Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021 - Market Newsdesk","og_description":"Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021 WILMINGTON, Del.–(BUSINESS WIRE)– Incyte (Nasdaq:INCY) today announced that multiple abstracts from its dermatology portfolio highlighting data on ruxolitinib cream, a selective JAK1\/JAK2 inhibitor designed for topical application, in patients with atopic dermatitis (AD) will be presented at the Society for Investigative Dermatology (SID) Virtual Meeting 2021, held virtually from May 3-8, 2021. \u201cAtopic dermatitis is a chronic inflammatory skin condition that can have serious impacts on patients\u2019 quality of life,\u201d said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte. \u201cWe are pleased to present data that highlight the potential of ruxolitinib cream as an effective … Continue reading \"Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-03T12:03:58+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210503005077r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021","datePublished":"2021-05-03T12:03:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/"},"wordCount":845,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210503005077r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/","name":"Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210503005077r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-05-03T12:03:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210503005077r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210503005077r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/incyte-announces-data-on-ruxolitinib-cream-in-atopic-dermatitis-accepted-for-presentation-at-the-society-for-investigative-dermatology-sid-virtual-meeting-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/485668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=485668"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/485668\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=485668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=485668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=485668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}